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ABSTRACT 
Fibrillin-1 is a large glycoprotein encoded by the FBN1 gene in humans. It provides strength and 
elasticity to connective tissues and is involved in regulating the bioavailability of the growth factor 
TGFβ. Mutations in FBN1 may be associated with depleted or abnormal adipose tissue, seen in some 
patients with Marfan syndrome and lipodystrophies. As this lack of adipose tissue does not result in 
high morbidity or mortality, it is generally underappreciated but is a cause of psychosocial problems. 
We examined the role of fibrillin-1 in adipogenesis. In inbred mouse strains we found significant 
variation in the level of expression in the Fbn1 gene that correlated with variation in several 
measures of body fat, suggesting that mouse fibrillin-1 is associated with the level of fat tissue. 
Furthermore, we found that FBN1 mRNA was up-regulated in the adipose tissue of obese women 
compared to non-obese, and associated with an increase in adipocyte size. We used human 
mesenchymal stem cells differentiated in culture to adipocytes to show that fibrillin-1 declines after 
the initiation of differentiation. Gene expression results from a similar experiment (available through 
the FANTOM5 project) revealed that the decline in fibrillin-1 protein was paralleled by a decline in 
FBN1 mRNA. Examination of the FBN1 gene showed that the region commonly affected in FBN1-
associated lipodystrophy is highly conserved both across the three human fibrillin genes and across 
genes encoding fibrillin-1 in vertebrates.  These results suggest that fibrillin-1 is involved as the 
undifferentiated mesenchymal stem cells transition to adipogenesis but then declines as the 
developing adipocytes take on their final phenotype. Since the C-terminal peptide of fibrillin-1 is a 
glucogenic hormone, individuals with low fibrillin-1 (for example with FBN1 mutations associated 
with lipodystrophy) may fail to differentiate and/or to accumulate adipocyte lipids, although this 
needs to be shown experimentally. 
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1. INTRODUCTION 
Fibrillin-1 is a large glycoprotein encoded in humans by the FBN1 gene (MIM 134797). It is strongly 
expressed in tissues of mesenchymal origin and localises to the extracellular matrix (ECM)1 [1, 2] 
where it contributes to strength and elasticity of tissues [3] and regulates the bioavailability of 
transforming growth factor beta (TGF-β) [4-7]. Mutations in FBN1 result in multisystem 
abnormalities of connective tissues, most frequently manifesting as Marfan syndrome (MFS) in 
humans (MIM 154700). MFS affects the skeletal, ocular and cardiovascular systems, with major 
morbidity and mortality arising from dilatation and dissection of the ascending aorta. In some 
individuals with FBN1 mutations, there is also a marked lack of subcutaneous adipose tissue, 
resulting in an abnormally thin phenotype (for example, see [8]). Extreme cases of lipodystrophy 
with or without Marfanoid features have been associated with mutations at the 3’ end of the FBN1 
gene [9-14].  Although this phenotype is not specifically associated with mortality in MFS patients, it 
causes considerable psychosocial stress, particularly to vulnerable youths who are already struggling 
to adjust to the diagnosis of a life-threatening condition and have significant body image issues [15, 
16].  This body morphology impacts on self-image and on the way patients interact with their peers. 
At the other end of the scale, obesity affects nearly 10% of the world’s population [17] and is a major 
financial and psychological burden to high income countries. Understanding the normal role of 
fibrillin-1 in generating adipose tissue could lead to therapies to ameliorate problems relating to 
both overweight and underweight. 
The function of fibrillin-1 in determining the level of adipose tissue has not been rigorously 
addressed. The Fbn1 gene is strongly expressed by mouse cells of adipocyte lineage [1]. Fibrillin-1 is 
secreted by rat adipocytes [18] and, as mentioned above, the phenotype associated with human 
FBN1 mutations frequently (but not always) involves depletion of subcutaneous adipose tissue. A 
genotype-phenotype correlation exists between the lipodystrophy phenotype and frameshift 
                                                          
1
 Abbreviations: ADSMC adipose derived mesenchymal stem cells; BMI body mass index; CAGE cap analysis of 
gene expression; ECM extracellular matrix; GO gene ontology; MFS Marfan syndrome;  
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mutations at the 3’ end of the FBN1 gene, in the second last exon, coding Exon 64 (UMD; shown as 
Exon 65 in the Ensembl Genome Browser) [9-14]. Reduced subcutaneous tissue and abnormal 
adipocytes can also be associated with mutations in central exons, for example in our patient with a 
mutation in exon 25 [8], clearly indicating that fibrillin-1 is involved in determining the formation and 
maturation of adipocytes.  
Adipose tissue develops through a cascade of events leading to conversion of mesenchymal stem 
cells to preadipocytes which undergo terminal differentiation into adipocytes. This process is 
regulated by key transcription factors CEBP (CCAAT enhancer binding protein) and PPARG 
(peroxisome proliferator activated receptor gamma) [19, 20]. Once proliferation of adipocyte 
precursors has ceased, lipid-filled storage vacuoles form in the intracellular space [21]. Adipocytes 
are constantly replenished in adult tissues (approximately 10% per annum [22]) and response to 
alterations in nutritional status can involve changes in both cell size and number (for example, [23-
25]). Understanding the factors regulating adipocyte differentiation offers the potential of 
treatments for obesity (adipose excess) as well as lipodystrophy (adipose deficiency). 
Adipogenesis can be seen as having two phases (reviewed extensively by [26]). In the early phase 
cells become committed to differentiation and in the later phase cells expand to accommodate the 
requirements of lipid storage. The ECM is extensively reorganised during this process, with down-
regulation of most secreted proteins and up-regulation of basement membrane and basal lamina. 
Over 65 proteins make up the ECM of adipose tissue [26] including fibrillin-1, fibronectin, a range of 
collagen subunits, osteonectin and latent transforming growth factor binding protein 1 (LTBP1), a 
member of the fibrillin gene superfamily. During preadipocyte formation from mesenchymal stem 
cells collagen type VI increases in amount and provides a scaffold for a lipid monolayer. The 
extracellular matrix of the preadipocytes then undergoes gradual up-regulation of collagen type IV 
[27], which interacts with collagen type VI, and collagen type V. Fibrillar collagens (type I and type 
III), fibronectin and other ECM components may peak early in differentiation before being down-
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regulated. As differentiation progresses, the ECM is reorganised to provide storage space for lipid 
vacuoles. The ECM in mature adipose tissue is under constant turnover to ensure that adequate lipid 
storage space is available [26, 28].  
The process of adipogenesis can be recreated in vitro using primary mesenchymal stem cells, treated 
with growth factors to promote differentiation along the adipose lineage. In this paper we describe 
investigations of the role of fibrillin-1 in adipogenesis in vitro and adipose expansion in vivo, based 
on independent experiments using either microarray or promoter expression analysis derived from 
the FANTOM5 project [29, 30]. 
 
2. MATERIALS AND METHODS 
2.1. Analysis of mouse gene expression across straing. 
Mouse gene expression data were downloaded from BioGPS [31]. Gene expression in mouse 
epididymal adipose tissue was derived from data presented in [32] , based on a customised 
microarray platform GNF1M. There was one probeset for Fbn1 (gnf1m00711_a_at) and one for Fbn2 
(gnf1m02242).  Available results were from pooled RNA obtained from mice at 25 weeks of age, of 
the following mouse strains: C57BL/6J (n=3), C3H/HeJ (n=4), CBA/J (n=2), DBA/2J (n=3).  To find 
genes with similar expressions to Fbn1, the Correlation function in BioGPS was used, with minimal 
correlation coefficient set at 0.75. Mouse phenotype data were obtained from the Mouse Phenome 
Database (MPD; [33]) which provides results for mice scanned immediately post-mortem using 
mouse densitometer dual energy X-ray absorptiometry (PIXImus mouse densitometer (LUNAR, 
Madison, WI). Details of the mouse husbandry are available at 
http://phenome.jax.org/db/q?rtn=projects/docstatic&doc=Jaxpheno1/Jaxpheno1_Animal. Results 
for MPD data set Jaxpheno1 were downloaded for body weight, body fat tissue weight and body fat 
percentage for males and females aged 8 and 16 weeks. Results for single nucleotide polymorphisms 
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for C57Bl/6J, C3H/HeJ and DBA/2J strains were retrieved from MPD and the Mouse Genome 
Informatics database (MGI; [34]). The mouse Fbn1 transcription start site region was identified using 
data from the FANTOM3 [35] and FANTOM5 projects  and the coordinates on the current build of 
the mouse genome (GRC m38.p4) determined by a BLASTN search in Ensembl [36].  
2.2. Analysis of human adipose tissue gene expression data. 
Gene expression data from the adipose tissue of a previously analysed cohort of 30 obese (BMI > 30 
kg/m2) and 26 non-obese (BMI < 30 kg/m2) women [37] was subjected to Significance Analysis of 
Microarrays [38]. Affymetrix microarray data from 114 adult Swedish women without diabetes [39] 
was examined for correlations between markers of adiposity and FBN1 expression with the 
statistical package Statview (SAS Institute Inc, NC, USA). The human FBN1 transcription start site was 
identified using data from the FANTOM3 and FANTOM5 projects [2, 29, 35].  
2.3. Detection of fibrillin-1 protein during adipogenesis. 
To assess further the impact of adipogenesis on fibrillin1, cryopreserved adipose derived 
mesenchymal stem cells (ADSMC) from a single female donor who had undergone abdominal 
liposuction were obtained from the Edinburgh Adipose Tissue Bank, University of Edinburgh, UK 
[40]. The research was approved by the South East Scotland Research Ethics Committee 03 
(Reference 1-0/S1103/45). The cells were cultured initially in DMEM (Gibco, Life Technologies Lit, 
Paisley UK) with 10% heat inactivated foetal bovine serum (GE Healthcare, Little Chalfont, UK), 1 X 
GlutaMAX (Gibco), 1 µg/µL bFGF (PeproTech, Rocky Hills, NJ, USA), at 37°C and 5% CO2.  Culture 
vessels were coated with 0.1% gelatin. Seeding density was 20,000 cells per well when using 8-well 
chamber slides (NUNC) and 50,000 cells per well when using 6 well plates. StemPro® Adipogenesis 
Differentiation Medium (Fisher Scientific, Loughborough UK) was prepared according to 
manufacturer’s instructions and filtered through a 500 mL 75 mm 0.45µm filter unit (Thermo 
Scientific, Leicestershire, UK). Cells were transferred to this medium after 24 hours when 75-80% 
confluency had been achieved. 100 µL (chamber slides) or 1 mL (6 well plates) of StemPro® 
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Adipogenesis Differentiation Medium was then added to the cells while DMEM with foetal bovine 
serum, GlutaMAX and bFGF as above was added to the control (non-differentiating) samples. 
Samples for immunocytochemistry (in the 8-well chamber slides) were fixed with 95% ethanol, 5% 
acetic acid for 20 minutes at -20°C. Slides were stained for fibrillin-1 as described previously [2] using 
a mouse monoclonal anti-fibrillin-1 antibody (11C1.3 ab3090, Abcam, Cambridge, UK) and 
AlexaFluor-488 labelled goat anti-mouse anti-IgG second antibody (Invitrogen, Paisley, UK). 
Oil Red O stock solution was prepared with 0.7g Oil Red O (Sigma-Aldrich) and 200 mL isopropanol, 
stirred overnight and filtered through a 0.2 µm filter unit. The solution was stored at room 
temperature and a working solution was prepared at 6:4 (v/v) Oil Red O stock solution and distilled 
water. This was incubated at room temperature for 20 minutes and then filtered through a 0.2 µm 
Millex syringe filter unit (Millipore, Cork, Ireland). Samples for Oil Red O staining (in 6-well plates) 
were fixed with 10% neutral buffered formalin solution (Sigma Aldrich) for 5 minutes, and then in 
fresh formalin solution at room temperature for one hour. The wells were briefly washed with 60% 
isopropanol and allowed to air dry at room temperature. 200 µL of Oil Red O working solution was 
added to each well, for 10 minutes at room temperature, then the wells were washed with distilled 
water four times for 10 minutes. Wells were imaged using an Axio Lab.A1 microscope (Zeiss). 
2.4. CAGE analysis of FBN1 expression during human adipogenesis.  
We examined gene expression and promoter usage in humans from a publicly available time course 
of adipogenesis using a different donor. Details of this experiment have been published elsewhere 
(Auxiliary File S1 of [30]) and the data are available for download at the FANTOM5 website [30]. 
Briefly, adipose-derived stem cells were extracted from the stromal vascular fraction of 
subcutaneous white adipose tissue from a single male donor, expanded and subcultured in vitro and 
treated to undergo differentiation to adipocytes [41-43]. RNA was harvested for cap analysis of gene 
expression (CAGE) analysis as part of the FANTOM5 project [29, 30]. Following the FANTOM5 quality 
control process [29, 30]. some time points were removed for some replicates. For the present 
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analysis, the time points analysed were Replicate 1: 3 hrs, 1 day, 2 days, 4 days, 8 days, 12 days, 14 
days post induction of differentiation; Replicate 2: 0 hrs, 2 days, 8 days, 12 days, 14 days post 
induction; Replicate 3: 0 hrs, 3 hrs, 1 day, 2 days, 4 days, 8 days, 12 days post induction. In addition, 
another set of samples from the same study was examined for FBN1 expression during adipogenesis. 
These samples consisted of adipocyte precursor cells isolated from the adipose stromal vascular 
fraction of four additional donors, differentiated without cell passage and sampled at three time 
points (day 4, day 8 and day 12). The gene based and promoter based data for these experiments 
were downloaded from the FANTOM5 website. Gene expression patterns were clustered using 
BioLayout Express3D [44, 45]. Pearson correlation coefficients and MCL inflation values used for 
different analyses are given in the results. Gene Ontology (GO) term enrichment in the generated 
clusters was analysed using the Database for Annotation, Visualisation and Integrated Discovery 
(DAVID) v6.7 [46] using total human genes as background.  
2.5. Evolutionary conservation of the lipodystrophy region of FBN1. 
Predicted amino acid sequences of exon 64 (based on the human sequence) of fibrillin-1, fibrillin-2 
and fibrillin-3 were extracted from the Ensembl database  for the following species: human (Homo 
sapiens), mouse (Mus musculus), sheep (Ovis aries), ferret (Mustela putorius furo), bushbaby 
(Otolemur garnettii), armadillo (Dasypus novemcinctus), panda (Ailuropoda melanoleuca), chicken 
(Gallus gallus), flycatcher (Ficedula albicollis), turkey (Meleagris gallopavo), coelacanth (Latimeria 
chalumnae), fugu (Takifugu rubripes), medaka(Oryzias latipes), spotted gar (Lepisosteus oculatus), 
stickleback (Gasterosteus aculeatus), tetraodon (Tetraodon nigroviridis), tilapia (Oreochromis 
niloticus) and Chinese soft shell turtle (Pelodiscus sinensis). The sequences were aligned using 
ClustalW (DNASTAR, Lasergene, Madison WI USA). Percent identity was based on sequence 
displacement values determined by the ClustalW alignment. Conserved amino acid residues were 
identified manually within the alignments.  
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3. RESULTS 
3.1. Fbn1 gene expression correlates with amount of adipose tissue in mouse 
The expression data available at BioGPS for different mouse strains indicate considerable variation in 
expression of Fbn1 in epididymal adipose tissue from males of different mouse strains (Figure 1A). 
The expression of the fibrillin gene family member Fbn2 was very low in adipose tissue and Fbn1 
expression was much lower in other tissues such as liver (Figure 1A), hippocampus and pancreas 
across strains. To assess the impact of the variability of Fbn1 expression in adipose tissue, we used 
data available through MGI. We compared results for four strains of mice: DBA/2J (high expression 
of Fbn1), CBA/J (moderate to high expression), C3H/HeJ (low to moderate expression) and C57Bl/6J 
(low expression) (Figure 1A). At 16 weeks, female C57BL/6J and C3H/HeJ were not different in body 
weight and nor were female CBA/J and DBN/2J. However female C57BL/6J and C3H/HeJ were both 
significantly lower in body weight than CBA/J and DBA/2J (Figure 1B).  Male C3H/HeJ were lower in 
body weight than C57BL/6J and C3H/HeJ were also lower than CBA/J male mice. This suggested a 
possible relationship between body weight and Fbn1 levels, particularly for females. To determine 
whether this was due to differences in adipose tissue, we examined body fat tissue weight and body 
fat percent in both males and females at 16 weeks (Figure 1B), with C57Bl/6J showing a significant 
difference from CBA/J and DBA/6J for both males and females. C3H/HeJ tended to have 
intermediate values.  We then investigated correlations between measures of body fat and Fbn1 
expression level, using the data available at BioGPS. In both males and females at 16 weeks Fbn1 
probeset gnf1m00711_a_at showed a high correlation with measures of body fat (Figure 1C). These 
results suggest that there is an association between Fbn1 mRNA levels and the deposition of adipose 
tissue in mouse.  
Analysis of SNP alleles in the four mouse strains (see Section 2.1) showed that C57BL/6J carried a 
different haplotype for the majority of the Fbn1 gene sequence (Figure 1D), although DBA/2J shared 
this haplotype at the 3’ end of the gene. There were two missense mutations resulting in a coding 
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change where the genotype differs between C57BL/6J and DBA/2J, one where CBA/J and C3H/HeJ 
also carry the C57BL/6J allele. No splice junction or stop codon mutations were segregating in these 
four strains, and the majority of the segregating SNPs were intronic. C57Bl/6J mice also had a single 
base deletion just upstream of the transcription start site region. No other promoter region 
differences were found. The extensive genetic difference between the Fbn1 genes of the C57BL/6J 
strain and the other three strains may explain the lower Fbn1 expression level in this strain. There 
were minimal differences among the other three strains except at the 3’ end of the gene (Figure 1D).  
In order to find genes that were coexpressed with Fbn1 in mouse adipose tissue, we identified those 
whose expression pattern was correlated with Fbn1 (correlation coefficient ≥ 0.75) across all mouse 
strains available for the eQTL analysis using the Correlation function of BioGPS. The list (available in 
[47]) included a number of genes previously found to be coexpressed with Fbn1 in C57BL/6 mice 
across a wide range of cell types [1] (Bgn, Cd248, Col1a2, Col3a1, Col4a1, Col4a2, Col5a1, Fn1, Fstl1, 
Lox, Ppic, SerpinH1, Sparc), indicating that these genes may be under similar regulatory control. 
3.2. FBN1 gene expression correlates with markers of adiposity in humans 
FBN1 mRNA levels were significantly up-regulated on average in abdominal white adipose tissue of 
obese women subjects compared with non-obese women (21% at false discovery rate 0.05)   [37] 
(Figure 1E). As with the mice, FBN2 was not differentially expressed in obese compared with normal 
women in this study (not shown). In a separate cohort of Swedish women [39], there was a small but 
significant correlation between FBN1 expression levels (measured by expression microarray) and 
body mass index, percentage body fat and fat cell volume (Table 1). Body mass index, percentage 
body fat and fat cell volume were highly correlated with each other and the correlations with FBN1 
mRNA are not independent.  FBN1 level was not correlated with fat cell number (Table 1). This 
suggests that fibrillin-1 is involved in human fat mass and that a high level is associated with 
expansion of hypertrophic adipose tissue through increased fat cell volume rather than number. 
More than 15,000 genetic variants have been detected in the human FBN1 gene (see, for example, 
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dbSNP; [48]), many in the promoter region, which could be associated with the differential 
expression in human subjects.  
3.3. Fibrillin-1 protein disappears as human ADMSC undergo differentiation. 
Since the examination of Fbn1 gene expression in mouse suggested a correlation with the level of 
adipose tissue in the different strains, we next examined FBN1 gene expression during a time course 
of human adipogenesis in vitro. We used a sample of adipose derived mesenchymal stem cells 
(ADMSC) which were stimulated to undergo differentiation in the adipocyte lineage, and compared 
fibrillin expression level with that in an undifferentiated culture of the same cells. Three replicates 
from a single donor were studied. The differentiated ADSMC cultures showed increasing amounts of 
Oil Red O staining (indicative of lipid production) as the time course progressed (Figure 2A), with 
lipid droplets appearing in unstained cultures by Day 3, accumulating in number and size up to Day 
18. Small oil droplets were also visible within the cytoplasm of unstained cells (not shown) by Day 
18. Non-differentiated controls showed minimal red staining at the later time points (Day 6 and Day 
18) (Figure 2A). Therefore, the adipogenic differentiation appeared to have been successful. 
Fluorescent immunocytochemistry was performed for fibrillin-1 protein during the adipogenesis 
time course. This revealed that both treated and control samples had a developing network of 
fibrillin-1 microfibrils at Day 1 (that is, after 24 hours in normal medium and a further 24 hours in 
adipogenesis medium). For the untreated cells, the matrix increased over the time course and by 
Day 14 there was an extensive presence of fibrillin-1 microfibrils as seen in Figure 2B.This matrix was 
similar to that previously described for fibroblasts [2], osteosarcoma cells [49]  and chondrocytes 
(MR Davis, unpublished results). In contrast, the differentiated cells showed initial formation of 
fibrillin-1 microfibrils at Day 1, but these did not elaborate and by Day 3 had begun to disappear. At 
Day 7 and Day 14 there was very little evidence of fibrillin-1 in the extracellular matrix of the treated 
cells (Figure 2B). 
3.4. FBN1 mRNA is down-regulated early in adipogenesis 
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The analysis of fibrillin-1 protein suggested that the amount of fibrillin declines rapidly after the 
onset of adipogenic differentiation (Figure 2B). Preliminary analysis using gene expression 
microarary and quantitative reverse transcriptase polymerase chain reaction showed that there was 
a decline in FBN1 mRNA during the differentiation time course used for immunofluorescence 
staining (not shown). To examine further the pattern of FBN1 mRNA expression during adipogenesis, 
we analysed a gene expression dataset which explored a similar but more extensive time course of 
adipogenic differentiation from mesenchymal stem cells. This study, which has been described 
previously [30], looked at gene expression using Cap Analysis of Gene Expression (CAGE), a 
quantitative method to assess promoter usage and hence gene expression [50]. The three replicates 
(from a single donor) of this study were used to examine the expression of fibrillin genes during 
adipogenesis from mesenchymal stem cells. Validation that adipogenesis had occurred is described 
elsewhere (Auxiliary Table S2 of [30]). Gene expression results (given as normalised tags per million, 
tpm) from RNA sampled at time points between 3 h and 14 days after initiation of differentiation 
were used. FBN1 mRNA level increased slightly in the first two days of differentiation but then 
declined considerably by day 4 (Figure 3A). Analysis of FBN1 expression in preadipocytes (from four 
different donors) differentiated into adipocytes and sampled at three time points (Day 04, Day 08 
and Day 12) further confirmed consistent and significant down-regulation of FBN1 during human 
adipogenesis (Figure 3B). Thus cells from six different donors showed consistent down-regulation of 
fibrillin-1 mRNA or protein after several days in differentiation medium. 
Since we had previously shown some differential promoter usage by fibrillin genes in different cell 
types [2], we examined FBN1 promoter usage in the MSC-adipocyte differentiation time course. 
There was no evidence of promoter switching during the time course (Figure 3C). The highest 
expressing FBN1 promoters (p1@FBN1, p2@FBN1 and p3@FBN1) were down-regulated in all 
replicates as differentiation proceeded. The remaining promoters showed very low activity, except 
for p13@FBN1 which exhibited roughly balanced bilateral expression in all three replicates in the 
first 24 hours (Figure 3D), suggesting that it may have enhancer activity in this system [51]. In the 
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sample of adipose nuclei in the Roadmap Epigenomics Project [52], there was evidence of 
monomethylation of Histone 3 lysine 4 (H3K4me1; frequently found at enhancers) and acetylation of 
Histone 3 lysine 27 (H3K27ac; found at promoters and enhancers)[53] at a higher level in the region 
of p13@FBN1 than p1@FBN1. Leucocytes had very low levels of these epigenetic marks, consistent 
with the tissue specificity of enhancer histone modification patterns [54].  
3.5. FBN1 is coexpressed with other mesenchymal genes during human adipogenesis in vitro.  
Using the full gene expression data set from the previous study [30] we generated a network graph 
containing 7,252 nodes (genes) connected by 688,617 edges (correlation in expression pattern of 
0.85 or greater) with BioLayout Express3D. Clustering with an MCL inflation value of 2.2 generated 29 
coexpression clusters of 10 or more nodes.  The list of genes in each cluster is available in [47].  The 
network layout and average expression profile of up- and down-regulated clusters are shown in [47]. 
There was a temporal transition from Cluster 02 (genes that are down-regulated rapldly early in 
differentiation) to Cluster 04 (genes down-regulated more gradually including FBN2 and FN1 
encoding fibronectin), Cluster 06 (genes whose expression persists through the first two days of 
differentiation, including FBN1) and Cluster 03 (genes with a peak of expression after the initiation of 
differentiation). Cluster 07 and Cluster 01 contain genes that are expressed in differentiated 
adipocytes, and peak at the end of the differentiation time course. The FBN1 gene was found in a 
cluster of genes that were down-regulated after 1-2 days in culture. In addition to FBN1, Cluster 06 
contained genes associated with GO terms for ECM, cell adhesion, mesoderm development, 
endoplasmic reticulum and osteoblast [47].  
 We have previously shown coexpression of connective tissue genes with FBN1 in mouse and 
humans [1, 2]. A number of these were down-regulated during adipogenesis.  Clustered tightly with 
FBN1 in this analysis was a set of mesenchymal genes previously been shown to be  coexpressed 
with mouse and human FBN1,including BGN, COL1A1, COL1A2, COL6A1, COL6A2, COL16A1, EFEMP2, 
FKBP10, LIX1L, MRGPRF, NFATC4, TIMP1 and  TIMP2 [1, 55, 56]. The down-regulated cluster which 
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contained the related gene FBN2, also contained other genes often coexpressed with FBN1 (for 
example, ANTXR1, CALU, COPZ2, FN1, LOX, LTBP2, PTGIS, TIMP3, VGLL3) [1]. The largest down-
regulated cluster contained ACTA2, ATOH8, CALD1, LOXL1, PALLD, POSTN, PRRX1, PRRX2, PRSS23, 
PTX3, TGFB3, TGFB1I1 and THBS1, which have also been shown to be coexpressed with mouse Fbn1 
[1]. The coexpression of genes commonly associated with FBN1 indicates that general mesenchymal 
genes were shut down during adipogenesis, while mesenchymal genes encoding proteins specific to 
the specialised needs of adipose connective tissue, such as those encoding collagen type IV subunits, 
were up-regulated, as shown previously [30]. 
We analysed the dataset to identify transcription factors that might be involved in regulating the 
level of FBN1 during adipogenesis. We created a network layout for transcription factor gene 
expression using BioLayout Express3D and identified a cluster of transcription factors that were down-
regulated during adipogenesis (data available in [47]). DAVID analysis showed that these included 
transcription factors associated with embryonic development, and development of specialised adult 
tissues including bone, lung, nervous system and haematopoietic cells.  Genes for transcription 
factors that were down-regulated  just ahead of or with the down-regulation of FBN1 (from the 
initiation of adipogenesis, or within the first 24 hours) included a number that have previously been 
associated with regulation of FBN1, either because of the presence of a binding motif in the 
promoter region [35] (for example TEAD1, 2 and 4, RUNX1 and 2, KLF4, SNAI2, CEBPD and many 
genes encoding forkhead box (FOX) transcription factors) or because of motif activity [1]  (CIZ1, 
PRDM1, EGR1, 2 and 3, ATF6B, E2F4 and NFATC1 and 2).  
We also looked at genes coding for proteases that are involved in processing and degrading fibrillins. 
Profibrillin molecules are cleaved to the active form by furin [57-59]. The FURIN gene that encodes 
this protease  showed very low expression throughout the time course. In contrast, genes encoding 
proteases that degrade fibrillins, including MMP2, MMP3 and MMP14 [60], were highly expressed 
and peaked in activity at Day 2, consistent with the disappearance of fibrillin-1 microfibrils by Day 3 
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(proflie shown in [47]). Other matrix metalloproteinase genes (MMP1, MMP11) were down-
regulated while MMP15 was up-regulated, suggesting specific roles for these enzymes during 
adipogenesis. Three genes encoding inhibitors of MMPs (tissue inhibitor of matrix 
metalloproteinase; TIMP) were found to be down-regulated (TIMP1 and TIMP2 clustering with FBN1 
and TIMP3 with FBN2) while TIMP4 was up-regulated by day 4 of differentiation. These results 
indicate that the amount of fibrillin-1 protein is likely to be controlled by expression of FBN1 mRNA, 
by the presence of the processing enzyme furin and by the balance between the degradative 
proteases and their inhibitors. The net effect is to reduce the level of fibrillin as differentiation 
proceeds. 
3.6. The lipodystrophy region of FBN1 has been highly conserved through vertebrate evolution 
Seven patients with severe generalised lipodystrophy have been reported to have mutations in 
coding exon 64 of FBN1 [9-14]. All mutations resulted in premature stop codons (Figure 4A) and 
were concordant for loss of the C-terminal end of exon 64 and all of exon 65. Unlike the majority of 
the FBN1 exons [49, 61, 62]  the amino acid sequence encoded by Exon 64 was not highly similar 
among the three human fibrillin proteins, fibrillin-1, fibrillin-2 and fibrillin-3 (Figure 4B), except that 
the furin cleavage site (consensus sequence R-X-K/R-R) [63, 64], was retained. However, the entire 
exon was strongly conserved in fibrillin-1 across mammalian species with some reduction in 
similarity in more distantly related vertebrates (Figure 4C; see also Figure S1 of [13]). In fibrillin-1, 
there was striking conservation of the furin cleavage site and of the 15 amino acids immediately 
upstream of the common deleted region. All lipodystrophy mutations resulted in frame shifts that 
would result in termination of the protein before or just after the furin cleavage site, with loss of the 
glucogenic fragment  [13].  An additional patient has been reported with a missense mutation 
p.R2726W, which occurs immediately before the furin cleavage site (Figure 4A) and affects an 
arginine that is conserved across mammals and birds (Figure 4C). This mutation was shown to 
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prevent proteolytic cleavage of the protein [65]. The affected individual had isolated skeletal 
manifestations of MFS; there is no information about the level of subcutaneous fat. 
 
4. DISCUSSION 
In this study we have analysed several publicly available databases and a cell culture model of 
adipogenesis to examine the possible role of fibrillin-1 in adipogenesis. Firstly we showed that Fbn1 
level in mouse strains is correlated with the amount of adipose tissue (measured as total adipose or 
as percent fat). This relationship was true although the mRNA was derived from epididymal fat from 
male mice at 25 weeks and the weight and body fat composition were from both male and female 
mice at 16 weeks, indicating that it is likely to be a general feature of mouse adipose tissue and that 
fibrillin-1 is important to the synthesis and/or maintenance of adipose tissue in vivo. There was no 
similar relationship with the fibrillin family member Fbn2 (not shown), so this association appeared 
to reflect a specific role of fibrillin-1. Genetic variation in the promoter region of the Fbn1 gene may 
explain the differences in expression between DBA/J (high expression) and C57BL/6J (low 
expression). Higher FBN1 expression was also found in obese women than non-obese women and 
there was a significant correlation between FBN1 expression level and several measures of adiposity 
(including cell volume but not cell number) in 114 human female subjects. These results are 
consistent with the finding of reduced subcutaneous tissue with abnormal adipocytes in some 
Marfan syndrome patients (for example [8]) and in patients with FBN1 mutations causing 
lipodystrophy [9-14].  
We then used a cell culture model of adipogenesis to explore the timing fibrillin-1 expression during 
adipogenesis. In this model isolated human adipose derived mesenchymal stem cells were triggered 
to form adipocytes over a period of two weeks. Fibrillin-1 protein was present throughout the period 
in untreated cells which maintained their undifferentiated mesenchymal stem cell phenotype, but in 
treated cells the protein was present early in the time course and then disappeared, coinciding with 
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the appearance of oil droplets (confirmed by Oil Red O staining) from Day 3. To examine gene 
expression, we used publicly available data from a comparable time course [30] to confirm the 
decrease in mRNA level in differentiating mesenchymal stem cells. Similarly, during the transition of 
preadipocytes from four donors to adipocytes [30]  a consistent decrease of FBN1 mRNA was seen.  
FBN1 was one of a number of mesenchymal genes where the expression dropped after 24 hours in 
differentiation medium and the level remained low up to Day 14. Many of these down-regulated 
genes had previously been seen to be coexpressed with FBN1 [1, 2] and a number encoded 
transcription factors that have previously been suggested to regulate FBN1 [1, 35]. Adipogenesis 
appears to involve the down-regulation of generic ECM genes in this group and up-regulation of 
specialised ECM genes (including ADAMTS18, COL4A1, COL4A2) coding for proteins which facilitate 
the dynamic storage of lipid in adipose tissue. Taken together these results suggest that fibrillin-1 is 
associated with the establishment of the mesenchymal stem cell commitment but not terminal 
differentiation, at least in the adipocyte lineage. The elevated expression seen in mouse and human 
tissues, in contrast to decline during the synchronised adipogenesis of the in vitro culture model, 
indicates that there is likely to be a homeostatic role for fibrillin-1 in mature adipose tissue. FBN1 
level was correlated with cell volume rather than cell number, indicating that the role of fibrillin-1 is 
likely to be in aiding the metabolic and structural changes necessary for lipid deposition rather than 
in cell proliferation. 
Coding Exon 64 of the FBN1 gene is important for the role of fibrillin-1 in human adipose tissue, 
since individuals with mutations truncating the protein at this point have severe lipodystrophy. 
Although this region was not conserved across the three human fibrillins (other than the furin 
cleavage site), it was highly conserved throughout the mammalian FBN1 genes (see also Figure S1 of 
[13]). This suggests that the role in adipogenesis is specific to fibrillin-1, consistent with the low level 
of FBN2/Fbn2 mRNA in human and mouse adipogenesis. The peptide beyond the furin cleavage site, 
which would be absent in the lipodystrophy patients, is also essential for the secretion of fibrillin-1; 
proteins lacking the C terminal amino acids were retained within the cell [66].  
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It has recently it has been shown that the C-terminal 170 amino acids of fibrillin-1 (beyond the furin 
cleavage site) form a peptide hormone, now called asprosin [13], which shows a higher vertebrate 
similarity score than other fibrillin-1 exons. Asprosin is released from white adipose tissue in 
response to low dietary glucose and stimulates the liver to release glucose, triggering insulin release 
from the pancreas. This discovery is consistent with the correlation between FBN1 expression and 
obesity and provides a mechanism for the association between fibrillin-1 and body fat.  Since 
asprosin is produced from fibrillin-1 in white adipose tissue [13], it is consistent that individuals with 
more adipose would have higher FBN1 mRNA (as in Figure 1 and Table 1). It may also explain why 
some Marfan patients (such as our case with an exon 25 mutation [8]) have reduced adipose 
regardless of dietary intake while others have normal or even excess adipose and consequent type II 
diabetes (for example some members of the family described in [67]), since the production of 
asprosin would depend on whether the furin site was able to be cleaved to produce the C-terminal 
fragment. For individuals with haploinsufficient mutations, those with deletions of the 3' end of the 
gene, premature termination mutations or mutations that alter the structure to hide the site, the 
production of asprosin would be limited. In contrast, if a normal level of the fibrillin-1 protein is 
made (albeit dysfunctional) and the site is exposed and available, asprosin level would be regulated 
by external factors such as diet. 
It remains to be determined whether the disappearance of fibrilin-1 mRNA and protein during 
synchronised adipogenesis in vitro is a cause or a consequence of differentiation. In a mouse model 
of Marfan syndrome, many of the phenotypic effects have been attributed to function of fibrillin-1 in 
regulating the bioavailability of transforming growth factor β (TGFβ) family members [68, 69], 
(including activins and bone morphogenic proteins) which inhibit adipogenesis [70, 71]. One role of 
fibrillin-1 may be to sequester these molecules during the initial stage of precursor commitment to 
differentiation. Interestingly, three chromosome 15 loci in the same general region as FBN1 have 
been associated with body fat distribution [72], and one of these contains the gene encoding 
SMAD6, an inhibitor of TFGβ family member signalling [73] which has been associated with vascular 
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disease [74]. Fibrillin-1 also has an important structural function in the extracellular matrix. 
Remodelling of the extracellular matrix from fibrillar to laminar type accompanies adipose 
differentiation [75] and is necessary to accommodate the altered shape and functions of the mature 
adipocytes. Proteins within the preadipocyte matrix such as fibronectin and presumably fibrillin-1 
support an elongated fibroblast-like structure  [76] which  must be converted to the spherical shape 
of the mature adipocyte. Fibronectin forms the basis for fibrillin-1 assembly (reviewed in [77] and its 
mRNA was down-regulated ahead of FBN1 mRNA and protein. The reduction in fibrillin-1 protein 
may reflect the generalised down-regulation of connective tissue proteins during ECM remodelling. 
This remodelling is mediated by proteolytic degradation [78] which is consistent with the increased 
levels of protease mRNAs described here as differentiation proceeded.  
Our results suggest that fibrillin-1 has a role in adipogenesis, and that it could mediate a genetic 
influence on body fat distribution [39] via a mechanism involving expansion of adipocytes, triggered 
by the newly discovered cleavage product asprosin [13]. Two lines of indirect evidence support this: 
there was a correlation between fibrillin-1 expression level and amount of adipose tissue in mouse 
and human, and FBN1 mutations, particularly mutations in Exon 64 of the gene, impact on human 
fat deposition. This pattern of expression was similar to other ECM proteins including fibrillary 
collagens and fibronectin [26]. The relatively high level of mRNA seen in mature adipose tissues 
presumably reflects the constant turnover of ECM to maintain lipid storage capacity, and the 
production of the glucogenic cleavage product. This suggests that the lack of adipose tissue and 
consequent body image issues of MFS and lipodystrophy patients could be addressed by treatment 
with drugs that simulate the effect of the cleavage product. However this possibility must be 
supported by direct mechanistic experiments in fat cells or animal models. In addition it would be 
valuable to record measures of body fat status of patients with FBN1 mutations, so that the 
mutations which predispose to lipodystrophy can be further characterised. 
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5. CONCLUSIONS 
Down-regulation of FBN1 expression is associated the transition from stem cell to preadipocyte to 
adipocyte, although a maintenance level of fibrillin-1 in adipose tissue is necessary and likely 
responsible for an endocrine response to low dietary gulcose.  Targeting of FBN1 or the fibrillin-1 
protein may provide a therapeutic avenue for conditions where there is a deficiency of adipose 
tissue (such as Marfan syndrome and lipodystrophy) and for obesity and type II diabetes, responsible 
for a major health burden in today’s world.  
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Table 1. Correlation of FBN1 expression and markers of adiposity in women 
FBN1 vs Number of 
samples 
Correlation 
coefficient (r) 
Regression 
coefficient (r2) 
Significance (p) 
BMI 114 0.236 0.056 0.0114 
Percent body fat 103 0.324 0.105 0.0008 
Cell volume 114 0.284 0.081 0.0022 
Fat cell number 114 0.008 6.37 x10-5 0.9328 
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Figure legends 
Figure 1. Fibrillin gene expression in adipose tissues. 
A. Fbn1 (probeset gnf1m00711_a_at) and Fbn2 (probeset gnf1m02242) expression levels in tissues 
of four strains of mice. Data derived from [32] and available from BioGPS. Black – C57Bl/6J; hatched 
black – C3H/HeJ; grey – CBA/J; hatched Grey – DBA/2J. 
B. Body weight, body fat tissue mass (head excluded) and body fat percent for four strains of mice. 
Data derived from MPD, dataset jaxpheno1). Symbols are coded as for Figure 1A. Bars show 
significance (ANOVA). ***: p < 0.001; **: 0.001 < p < 0.01; *: 0.01 < p < 0.05 
C. Correlation between body weight, body fat tissue mass (head excluded) and body fat percent and 
Fbn1 expression. Circles represent females and squares males. Trendlines and regression coefficients 
were calculated using Microsoft Excel 2013. Symbols are coded as for Figure 1A. 
D. Single nucleotide polymorphism alleles in the mouse Fbn1 gene. Upper bar shows the structure of 
the gene with exons shown in black and introns in white. Lower bar shows the genotype of C3H/HeJ, 
CBA/J and DBA/2J mouse strains compared with C57BL/6J shown in black. White bars indicate 
missing data. Asterisk shows the location of a single base insertion relative to C57BL/6J.Two non-
synonymous coding variants are shown. C57BL/6J mice have D429 while DBA/2J mice have N429. 
C47BL/6J mice have A427 while the other lines have V427. 
E. FBN1 expression in obese (left) and non-obese (right) human females. Boxes show the boundaries 
of the first and third quartiles; bar shows the median value and whiskers show the minimum and 
maximum values. An average difference of 21% at a false discovery rate of 0.05 was found.  
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Figure 2. Human in vitro adipogenesis time course. 
A. Oil Red O staining showing formation of lipid droplets. Adipose derived mesenchymal stem cells 
(ADMSC), untreated (left panel) or differentiating to adipose (right panel) stained with Oil Red O at 1 
d, 3 d, 6 d, 8 d and 18 d after induction of differentiation. Red staining shows lipid droplets (darker 
grey surrounded by bright ring in print version). Images show results representative of three 
separate experiments. 0 time was similar to 1 day time point. Scale bars represent 50 µm. 
B. Fibrillin-1 immunocytochemistry. ADMSC untreated (left panel) or undergoing differentiation 
(right panel) were stained using a fluorescently-labelled anti-fibrillin-1 antibody. Nuclei are stained 
blue with DAPI and fibrillin-1 is shown by green fluorescence (white in print version). Images show 
results representative of three separate experiments. Scale bars represent 20 µm. 
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Figure 3. Fibrillin expression and promoter usage during adipogenesis. Expression levels were 
derived from transcription start site data [30] available at FANTOM5 website. 
A. FBN1 levels during the in vitro time course of adipogenesis from mesenchymal stem cells. Y axis 
shows the gene-based expression level, given as normalised tags per million (tpm); X axis shows the 
time points. Each replicate is shown separately. 
B. FBN1 levels during preadipocyte differentiation to adipocytes in four donors. Y axis shows the 
gene-based expression level, given as normalised tpm for each donor; X axis shows the time points. 
C. FBN1 promoter usage during adipogenesis. Promoters are numbered according to expression 
level across the whole FANTOM5 data set [29, 30], so p1@FBN1 is the highest expressing FBN1 
promoter over the whole data set.  Y axis shows the promoter-based expression level, given as 
normalised tags per million (tpm) averaged over three replicates; X axis shows the time points. Error 
bars show 1 standard deviation. 
D. Expression of p13@FBN1, showing bidirectional expression pattern (averaged normalised tpm). 
FBN1 is encoded on the reverse strand (left side of graph). Error bars show 1 standard deviation. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
26 
 
Figure 4. Conservation of the amino acid sequence of coding exon 64 of fibrillin proteins.  
A. Effect of five unique protein truncation mutations in human FBN1 on exon 64 sequence. 
Sequences were obtained from [9-14]. Mutant sequences are shown in bold and X represents an in 
frame termination codon. Also shown is a missense mutation c. 8176 C>T which results in 
substitution of arginine at position 2726 with tryptophan (p.R2726W; bolded W) which produced the 
skeletal phenotype of Marfan syndrome [65]. 
B. Amino acid sequence of exon 64 of human fibrillin-1, fibrillin-2 and fibrillin-3. Conserved residues 
are shown by asterisks below the sequences. Furin cleavage site is boxed. Data were derived from 
the Ensembl data base and sequence similarities determined using ClustalW as described in the 
methods. 
C. Amino acid sequence of Exon 64 of fibrillin-1 in a range of vertebrate species. Conserved residues 
are shown by asterisks below the sequences and are boxed in grey. Data were derived from the 
Ensembl data base and sequence similarities determined using ClustalW as described in the 
methods. All sequences were determined to be homologous to human coding exon 64 based on 
amino acid sequence homology and C-terminal location within the predicted protein. 
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Highlights  
FBN1 mRNA levels are associated with body weight in both humans and mice.  
Fibrillin-1 protein and RNA are produced early in adipogenesis and decline by day 3.  
FBN1 is co-expressed with mesenchymal markers and proteases during adipogenesis.  
The lipodystrophy region of FBN1 is highly conserved across mammals.  
The results explain the deficiency of adipose tissue in Marfan syndrome patients.  
